applications

Week 3, August 2024: VHH Antibodies Everywhere

VHH antibodies, also known as nanobodies, are single-domain antibodies that are derived from camelid heavy-chain antibodies. Due to their small size (~ 15 kDa) and diverse applications in bio-derived therapeutics, these antibodies have widespread attention in the research and development community, with some examples below from just this week!

Aug 20, 2024
The Unique Origin of VHH Antibodies: Camelids

Camelids provide the origin of VHH antibodies. Biointron highlights their unique biology, how VHHs are developed, and their growing use in diagnostics and therapy.

Jul 01, 2024
The Promise of VHH Antibodies

VHH antibodies offer stability, small size, and strong binding. Biointron highlights their promise in diagnostics, therapeutics, and next-generation antibody design.

Jun 05, 2024
Week 1, June 2024: Multi-Payload ADCs

Antibody-drug conjugates (ADCs) are made up of a monoclonal antibody linked to a cytotoxic drug (payload) through a stable chemical linker, enabling targeted delivery of the drug to specific cancer cells. The ideal ADC payload should have sufficient toxicity, low immunogenicity, high stability, and

Jun 04, 2024
Computational Design of Antibodies for Drug Discovery

AI is transforming antibody design. Biointron explores computational methods that accelerate drug discovery and optimize therapeutic development.

May 27, 2024
Week 2, May 2024: Computational Design of Antibodies

MAGMA-seq is an integrated technology for antibody wide mutational scanning. DOI:10.1038/s41467-024-48072-zThe use of bioinformatics and computational methods were of high interest in several papers published this past week. Protein language models, akin to natural language processing tools, p

May 15, 2024
Innovating Cancer Treatment: Bispecific Antibody Drug Conjugates

Bispecific ADCs advance oncology. Biointron shows how dual-targeted antibody-drug conjugates improve precision, efficacy, and patient outcomes in cancer treatment.

May 02, 2024
Week 5, Apr 2024: Immunosenescence

As we age, our innate and adaptive immune system undergoes various changes, typically characterized by decreased lymphopoiesis and adaptive immunity, and increased inflammation and myeloid pathologies. Immunosenescence (the gradual deterioration of the immune system associated with ageing), makes individuals more susceptible to infections, less responsive to vaccines, and prone to the development of chronic inflammatory conditions and autoimmune diseases.

Apr 30, 2024
Antibody Basics: Part 7 - Functions in the human body: Understanding the key roles of antibodies

Antibodies defend health by neutralizing pathogens, aiding phagocytosis, and activating complement. Biointron explains these vital functions in immunity and therapy.

Apr 27, 2024
Week 4, Apr 2024: Fc-Mediated Functions

Fc-mediated antibody effector functions play an important role in the humoral immune response and form a necessary link between innate and adaptive immunity. The constant (Fc) region is the tail portion of an antibody that interacts with other components of the immune system, such as immune cells and complement proteins. Well-known functions include opsonization, antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement activation.

Apr 23, 2024
Antibody Basics: Part 6 - Antibody formats: Antibody-Drug Conjugates (ADCs)

Antibody-drug conjugates unite precision with potency. Biointron outlines how ADCs combine antibodies with cytotoxic drugs to deliver targeted cancer therapies.

Apr 19, 2024
Week 3, Apr 2024: Bispecific ADCs

Bispecific antibody-drug conjugates (BsADCs) are a new class of therapeutic drugs being developed to fight cancer. They combine the dual targeting ability of bispecific antibodies with the cell-killing power of cytotoxic drugs. BsADCs are designed to deliver cytotoxic drugs directly to cancer cells, while minimizing damage to healthy cells. While they are still in development, several exciting advances have occurred recently.

Apr 16, 2024
Antibody Basics: Part 5 - Antibody Formats: Antibody fragments (Fab, F(ab')2, Fc)

Fab, F(ab’)2, and Fc fragments expand antibody applications. Biointron explains their structures and how they advance diagnostics, imaging, and therapeutic innovation.

Apr 10, 2024
Week 1, Mar 2024: Antibodies and Nucleocapsid Proteins

The nucleocapsid of a virus, which consists of the capsid enclosing the viral nucleic acid, can be a target for antibody therapies. When a virus infects a host, its nucleocapsid becomes exposed to the immune system, triggering the production of antibodies specific to proteins present on the nucleocapsid's surface, preventing the virus from entering host cells, disrupting its replication cycle, or marking it for destruction by other components of the immune system.

Mar 06, 2024
Week 4, Feb 2024: Antibodies for Toxins

Toxins are substances produced by living organisms, such as bacteria, fungi, plants, and animals, that are harmful to other organisms. Antibodies play a crucial role in immune responses for the body's defense against toxin intoxication, in addition to being invaluable tools for both diagnostic and therapeutic applications.

Feb 29, 2024

Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.